Evidence map›Paper›PMID 30774955›Full record

ArticleJournal of materials chemistry. B2016

Nanomaterial-Based Vaccine Adjuvants.

Bingbing Sun, Tian Xia

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of materials chemistry. B, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 133 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Advances in Vaccine Adjuvants: Nanomaterials and Small Molecules.Handbook of experimental pharmacology · 2024
    Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Bingbing SunDivision of NanoMedicine, Department of Medicine; University of California, Los Angeles, California, 90095, United States.
Tian XiaDivision of NanoMedicine, Department of Medicine; University of California, Los Angeles, California, 90095, United States.
Los Angeles City College · USUniversity of California, Los Angeles · US

Funding

Predictive Toxicological Paradigm for Chronic Nanoparticle Injury in the LungR01ES016746 · NIEHS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI NEL, ANDRE ELIAS · 2008 to 2017
$3.4M
Toxicological Profiling of Engineered Nanomaterials (ENMs) in the MPS (RES)U01ES027237 · NIEHS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI NEL, ANDRE ELIAS, XIA, TIAN · 2016 to 2020
$2.2M
Carbon Nanotube Structure-Activity Relationships for Predictive ToxicologyR01ES022698 · NIEHS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI HERSAM, MARK C., NEL, ANDRE ELIAS · 2014 to 2018
$2.1M
NIEHS NIH HHS R01 ES016746NIEHS NIH HHS R01 ES022698NIEHS NIH HHS U01 ES027237
6 · The paper itself

Abstract

Vaccination is a biological process that administrates antigenic materials to stimulate an individual's immune system to develop immunity to a specific pathogen. It is the most effective tool to prevent illness and death from infectious diseases or diseases leading to cancers. Because many recombinant and synthetic antigens are poorly immunogenic, adjuvant is essentially added to vaccine formula that can potentiate the immune responses, offer better protection against pathogens and reduce the amount of antigens needed for protective immunity. To date, there are nearly 100 different types of adjuvants associated with about 400 vaccines that are either commercially available or under development. Among these adjuvants, many of them are particulates and nano-scale in nature. Nanoparticles represent a wide range of materials with novel physicochemical properties that exhibit immunostimulatory effects. However, the mechanistic understandings on how their physicochemical properties affect immunopotentiation remain elusive. In this article, we aim to review current development status of nanomaterial-based vaccine adjuvants, and further discuss their acting mechanisms, understanding of which will benefit the rational design of effective vaccine adjuvants with improved immunogenicity for prevention of infectious disease as well as therapeutic cancer treatment.

Identifiers

PMID30774955
PMCPMC6377210
OpenAlexW2464695177

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.